WallStreetZenWallStreetZen

NASDAQ: ZVRA
Zevra Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Zevra Therapeutics revenue was $106.47M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2025) ending on Dec 31, 2025 was $34.1M, up 30.9% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, ZVRA annual revenue was $106.5M, with 350.9% growth year-over-year.

ZVRA past revenue growth

How has ZVRA's revenue growth performed historically?

Company
350.91%
Industry
379.98%
Market
88.6%
ZVRA's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ZVRA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ZVRA's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ZVRA revenue history

Current Revenue
$106.5M
Current Earnings
$83.2M
Current Profit Margin
78.2%

Be the first to know when ZVRA announces revenue.

ZVRA Revenue History By Year

ZVRA Yearly RevenueZVRA RevenueZVRA ChangeZVRA Revenue Growth
2025-12-31$106.47M$82.86M+350.91%
2024-12-31$23.61M-$3.85M-14.02%
2023-12-31$27.46M$17.30M+170.26%
2022-12-31$10.16M-$18.49M-64.53%
2021-12-31$28.65M$15.36M+115.61%
2020-12-31$13.29M$449.00k+3.50%
2019-12-31$12.84MN/AN/A
2018-12-31$0.00N/AN/A
2017-12-31$0.00N/AN/A
2016-12-31$0.00N/AN/A
2015-12-31$0.00N/AN/A
2014-12-31$0.00N/AN/A
2013-12-31$0.00N/AN/A

1 of 1

Zevra Therapeutics Revenue FAQ

What was ZVRA's revenue last quarter?

On Invalid Date, Zevra Therapeutics (NASDAQ: ZVRA) reported Q4 2025 revenue of $34.13 million up 183.36% year over year. In the same quarter last year, Zevra Therapeutics's revenue was $12.04 million.

What was Zevra Therapeutics's revenue in 2025?

Zevra Therapeutics's annual revenue for the twelve months ending Dec 31, 2025 was $106.47 million, a 350.91% increase year over year.

How much does Zevra Therapeutics make in a day?

Based on Zevra Therapeutics annual revenue for the past five years, ZVRA makes an average of $107,591.23 per day.

What was Zevra Therapeutics's annual revenue growth in the past year?

As of Q1 2026, Zevra Therapeutics's revenue has grown 350.91% year over year. This is 29.06 percentage points lower than the US Biotechnology industry revenue growth rate of 379.98%. Zevra Therapeutics's revenue in the past year totaled $106.47 million.

How much does Zevra Therapeutics make in a year?

Zevra Therapeutics's revenue by year for the past five years is:
  • Zevra Therapeutics's revenue for the twelve months ending Dec 31, 2025 was $106.47 million, a 350.91% increase year over year.
  • Zevra Therapeutics's annual revenue for Dec 31, 2024 was $23.61 million, a 14.02% decrease from 2023.
  • Zevra Therapeutics's annual revenue for 2023 was $27.46 million, a 170.26% increase from 2022.
  • Zevra Therapeutics's annual revenue for 2022 was $10.16 million, a 64.53% decrease from 2021.
  • Zevra Therapeutics's annual revenue for 2021 was $28.65 million, a 115.61% increase from 2020.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.